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Abstract
Low levels of sex hormone-binding globulin (SHBG) are considered
to be an indirect index of hyperinsulinemia, predicting the later onset
of diabetes mellitus type 2. In the insulin resistance state and in the
presence of an increased pancreatic ß-cell demand (e.g. obesity) both
absolute and relative increases in proinsulin secretion occur. In the
present study we investigated the correlation between SHBG and
pancreatic ß-cell secretion in men with different body compositions.
Eighteen young men (30.0 – 2.4 years) with normal glucose tolerance
and body mass indexes (BMI) ranging from 22.6 to 43.2 kg/m2 were
submitted to an oral glucose tolerance test (75 g) and baseline and 120-
min blood samples were used to determine insulin, proinsulin and C-
peptide by specific immunoassays. Baseline SHBG values were sig-
nificantly correlated with baseline insulin (r = -0.58, P<0.05), proinsu-
lin (r = -0.47, P<0.05), C-peptide (r = -0.55, P<0.05) and also with
proinsulin at 120 min after glucose load (r = -0.58, P<0.05). Stepwise
regression analysis revealed that proinsulin values at 120 min were the
strongest predictor of SHBG (r = -0.58, P<0.05). When subjects were
divided into obese (BMI >28 kg/m2, N = 8) and nonobese (BMI £ 25
kg/m2, N = 10) groups, significantly lower levels of SHBG were found
in the obese subjects. The obese group had significantly higher
baseline proinsulin, C-peptide and 120-min proinsulin and insulin
levels. For the first time using a specific assay for insulin determina-
tion, a strong inverse correlation between insulinemia and SHBG
levels was confirmed. The finding of a strong negative correlation
between SHBG levels and pancreatic ß-cell secretion, mainly for the
120-min post-glucose load proinsulin levels, reinforces the concept
that low SHBG levels are a suitable marker of increased pancreatic ß-
cell demand.
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Introduction
Sex hormone-binding globulin (SHBG),
a glycoprotein produced by the liver, is re-
sponsible for the transport of sex steroids,
mainly testosterone and dihydrotestosterone,
whereas it binds to estradiol (E2) with a
much lower affinity (1). Hepatocyte SHBG
production is under the influence of several
factors which can either increase (thyroid
hormones, estrogens) or reduce its levels
(obesity, progestogen, growth hormone, pro-
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lactin) (1,2). The inhibition of hepatic SHBG
synthesis by insulin has been demonstrated
in vitro (2). Many in vivo studies have shown
a strong negative correlation between SHBG
and insulinemia, leading to the speculation
that the globulin could be a marker of insulin
resistance (3,4). A physiological model of
this correlation can be found during puberty
when a significant decrease in SHBG levels
is observed along with a certain degree of
insulin resistance (2,5). The majority of the
studies which tried to establish correlations
between insulinemia and SHBG levels used
insulin assays with high cross-reactivity with
proinsulin.
For unknown reasons the correlation be-
tween sex steroids and insulinemia seems to
be different for females and males (2,6,7). In
animals, sex differences in androgen levels
and insulin sensitivity are confirmed by the
impaired insulin sensitivity observed in fe-
male rats under testosterone treatment. At
the same time, testosterone replacement im-
proves insulin sensitivity in castrated male
rats presenting insulin resistance (8). In hu-
mans these aspects have been less studied in
men than in women.
High levels of proinsulin are observed
when there is a dysfunctional or increased
demand on pancreatic ß-cells (9,10). This
pancreatic secretory disorder (hyperproin-
sulinemia) may precede the onset of diabetes
mellitus, both type 1 and 2 (11-13). The
proinsulin to insulin ratio and the absolute
concentration of proinsulin predict the de-
velopment of diabetes mellitus type 2, even
after adjustment for other risk factors such as
body mass index (BMI) and glucose toler-
ance status (10).
Although both SHBG and proinsulin are
related to pancreatic ß-cell dysfunction, there
is no study trying to correlate these two
proteins. Thus, the aim of the present study
was to evaluate the correlation between en-
docrine pancreatic secretion and SHBG a-
mong young men with different body com-
positions.
Subjects and Methods
Eighteen white men in good health, rang-
ing in age from 25 to 33 years (30.0 – 2.4),
with normal thyroid, hepatic and renal func-
tion (evaluated by measuring TSH, prothrom-
bin time and creatinine, respectively) were
studied. The subjects were not taking any
drugs and none of them had taken part in a
weight reduction program in the last four
months. None of the subjects had symptoms
or signs suggestive of sexual dysfunction or
hypogonadism. Anthropometric measure-
ments were performed on all participants, all
barefoot and casually dressed, and included
body weight, height, waist-to-hip ratio
(WHR) (waist circumference was recorded
at the narrowest point or at the umbilicus and
hip circumference at the level of the greater
trochanter) and BMI (kg/m2), which was
calculated as current measured weight in
kilograms divided by height in square meters.
Body fat percentage was recorded using dual
energy X-ray absorptiometry (DPX; Lunar
Radiation Corporation, Madison, WI).
Oral glucose tolerance test
Dietary advice was given for 3 days be-
fore the oral glucose tolerance test (OGTT)
to ensure an intake of at least 150 g of
carbohydrate per day. The subjects were
also advised to maintain their usual physical
activities for at least one week before the
test. After an overnight fast, a 75 g glucose
load was administered and blood samples
were drawn from an antecubital vein at
baseline and at 120 min for the determina-
tion of plasma glucose, insulin, proinsulin
and C-peptide. Blood samples were also
drawn at baseline for SHBG determination.
Only plasma glucose was measured immedi-
ately using the glucose oxidase method. The
rest of the samples were centrifuged imme-
diately after collection, and serum was stored
at -70oC until the time for assay. The defini-
tion of glucose tolerance was based on a 2-h
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oral glucose tolerance test according to World
Health Organization criteria (14).
Assays
Specific insulin, proinsulin and C-pep-
tide were measured in duplicate using com-
mercial radioimmunoassay kits (Linco Re-
search Inc., St. Charles, MO). For insulin the
limit of sensitivity was 2 µU/ml and the
intra- and interassay coefficients of variation
(CV) were <10%. Cross-reactivity with hu-
man proinsulin was <0.2% and with human
insulin 100%. The normal fasting range was
5-15 µU/ml. In the proinsulin assay the limit
of sensitivity was 2 pmol/l. Intra- and inter-
assay coefficients of variation were <10%.
Cross-reactivity with human insulin and hu-
man C-peptide was <0.1%. In the C-peptide
assay the limit of sensitivity was 0.1 ng/ml.
Intra- and interassay coefficients of varia-
tion were <10%. Cross-reactivity with hu-
man proinsulin was <4% and with human
insulin 0%. The molar ratio between proin-
sulin and insulin was calculated (proinsulin
divided by insulin levels at baseline) after
the conversion of insulin to pmol/l using 6.0
as a conversion factor. SHBG was measured
in duplicate using a commercial immunora-
diometric assay (Diagnostic Systems Labo-
ratories, Inc., Webster, TX). For SHBG the
limit of sensitivity was 3 nmol/l and the
intra-assay and interassay coefficients of
variation were <3.8% and <11.6%, respec-
tively. The experimental protocol was ap-
proved by the Ethics Committee of Escola
Paulista de Medicina, UNIFESP, and each
subject gave written consent to participate in
the study.
Statistical analysis
Data analysis was performed using a sta-
tistical software program (Jandel scientific
software 2.0, Jandel Corporation, San Rafael,
CA). The correlations between SHBG and
the other variables were established using
either Spearmans or Pearsons correlation
test when data were normally distributed. A
stepwise regression analysis using SHBG as
dependent variable and insulin, proinsulin
and C-peptide as independent variables was
also performed. Comparisons between sub-
groups (obese and nonobese) were performed
using the Mann-Whitney rank sum test when
data were not normally distributed or the
Student t-test when data were normally dis-
tributed. Results are reported as the means –
SD. The level of significance was set at
P<0.05.
Results
The characteristics of the study group are
shown in Table 1. The subjects enrolled in
this study were young (age range, 25 to 33
years). There was a wide distribution of
body composition and body fat, with nono-
bese and extremely obese subjects, as shown
by ranges for BMI, %fat and WHR of 22.6-
43.2 kg/m2, 12.7-40.6% and 0.81-1.01, re-
spectively. It should be emphasized that the
mean measurements for the group as a whole
Table 1 - Clinical and hormone characteristics of the sub-
jects.
BMI, Body mass index; DPX, dual energy X-ray absorptiom-
etry; WHR, waist-to-hip ratio; SHBG, sex hormone-binding
globulin.
Mean ± SD Range
BMI (kg/m2) 28.8 ± 6.3 22.6 - 43.2
DPX (%fat) 24.5 ± 8.9 12.7 - 40.6
Waist (cm) 98 ± 16 81 - 130
WHR 0.91 ± 0.04 0.81 - 1.01
Weight (kg) 91.7 ± 22.0 67.0 - 145.0
SHBG (nmol/l) 38.7 ± 13.4 14.0 - 73.0
Fasting proinsulin (pmol/l) 17.5 ± 14.2 8.0 - 70.0
120-min proinsulin (pmol/l) 41.3 ± 22.3 12.0 - 92.0
Fasting C-peptide (ng/ml) 2.1 ± 1.0 0.7 - 4.3
120-min C-peptide (ng/ml) 5.9 ± 3.5 0.9 - 14.2
Proinsulin/insulin 0.2 ± 0.2 0.02 - 0.97
Fasting glucose (mg/dl) 93 ± 8 82 - 118
120-min glucose (mg/dl) 101 ± 22 60 - 139
Fasting insulin (µU/ml) 15.9 ± 8.7 7.0 - 36.0
120-min insulin (µU/ml) 62.4 ± 64.2 10.8 - 247.7
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were typical of obesity and fat excess. Mean
values for BMI and %fat were 28.8 – 6.3 kg/
m2 and 24.5 – 8.9, respectively. In agree-
ment with the wide variation in body compo-
sition, pancreatic hormones at baseline and
120 min after the glucose load showed a
wide distribution. Baseline insulin ranged
from 7 to 36 µU/ml and post-glucose load
levels ranged from 10 to 247 µU/ml (Table
1). This range of values was also observed
for C-peptide and proinsulin. The whole
group showed a tendency to high mean val-
ues due to the prevalence of obesity.
Table 2 shows the correlations between
SHBG levels and other variables. SHBG
values were inversely correlated with %fat
and WHR, and no significant correlation
was found between SHBG and BMI, waist
circumference or weight. A significant nega-
tive correlation between fasting insulin, fast-
ing C-peptide, fasting and 120-min post-
glucose load proinsulin was found. There
was no significant correlation between SHBG
levels and the proinsulin/insulin molar ratio.
Stepwise regression analysis showed that
120-min proinsulin was strongly correlated
with, and thus was the best predictor of,
SHBG (r = -0.58; P = 0.012) (Figure 1).
For further comparison of SHBG and
pancreatic ß-cell profile related to different
body compositions the group was divided
into nonobese subjects (BMI £ 25 kg/m2) (N
=10) and obese subjects (BMI >28 kg/m2)
(N = 8) (Table 3). There were marked differ-
ences in all anthropometric measurements
(BMI, WHR, waist, weight and %fat). Obese
subjects showed significantly lower SHBG
levels, higher 120-min insulin, baseline and
120-min proinsulin (Table 3) and baseline
C-peptide levels than nonobese subjects. The
proinsulin/insulin molar ratio was not signif-
icantly different between subgroups even
though the obese group showed a higher
ratio than the nonobese group (0.26 – 0.29 vs
0.16 – 0.09, P = 0.054). Even though the
obese group showed higher 120-min glucose
values, the difference was not statistically
significant.
Discussion
In the present study we report for the first
time a negative correlation between SHBG
and baseline and post-glucose load proinsu-
lin levels, reinforcing the previous concept
that SHBG may be related to pancreatic ß-
cell secretion (15,16). This study, performed
using a highly specific insulin assay, has also
confirmed previous studies which found a
strong negative correlation between insulin
and SHBG (6,17-19).
Low SHBG levels have been shown to
predict diabetes mellitus type 2 in women
(3,6,20). It seems that decreased SHBG may
correspond to an initial stage in the develop-
ment of diabetes mellitus type 2, probably
linked to hyperinsulinemia imposed on hepa-
Table 2 - Correlations between SHBG and other
variables.
*P<0.05 (Pearson or Spearman test). For abbre-
viations, see Table 1.
BMI r = -0.41 P = 0.08
DPX (%fat) r = -0.53 P = 0.02*
Waist r = -0.38 P = 0.11
WHR r = -0.53 P = 0.02*
Weight r = -0.33 P = 0.15
Fasting proinsulin r = -0.47 P = 0.047*
120-min proinsulin r = -0.58 P = 0.01*
Fasting C-peptide r = -0.55 P = 0.01*
120-min C-peptide r = -0.38 P = 0.12
Proinsulin/insulin r = 0.10 P = 0.68
Fasting glucose r = -0.20 P = 0.40
120-min glucose r = -0.36 P = 0.13
Fasting insulin r = -0.53 P = 0.02*
120 min-insulin r = -0.44 P = 0.06
Figure 1 - Relationship between
SHBG levels and 120-min proin-
sulin after a glucose load test in
men.
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tocytes (4). A direct inhibitory effect of insu-
lin on SHBG release was shown in vitro
using cultures of a line of transformed hu-
man hepatocytes (HepG2) (2,21). Yki-
Järvinen et al. (16) theorized that portal insu-
lin concentrations rather than insulin sensi-
tivity regulate SHBG, and concluded that the
globulin could only be used as a marker of
insulin sensitivity in individuals with intact
insulin secretion. In other studies, Peiris et
al. (18) demonstrated the relationship of in-
sulin secretory pulse frequency with SHBG
without any association with insulin secre-
tory pulse amplitude. Most of the studies on
the establishment of in vivo and in vitro
correlations between SHBG and insulinemia
utilized insulin assays having high cross-
reactivity with proinsulin levels, possibly
masking the proinsulin interrelationships.
It is well established that in states of
pancreatic ß-cell functional disorder there is
an increase in proinsulin secretion (10-13,22).
The activity of proinsulin in stimulating pe-
ripheral disposal of glucose is approximately
1-8% that of insulin in the basal state (23,24).
When hyperproinsulinemia occurs this bio-
logical effect may be enhanced. We may
assume that in both the above situations
(portal insulinemia and secretory frequency
of insulin pulses) proinsulin in addition to
insulin may be concomitantly effective. In
physiological conditions small amounts of
proinsulin are released by pancreatic ß-cell
granules at a rate that can reach up to 15% of
the total secretion. Furthermore, the insulin
half-life is less than that of proinsulin, about
3.5 and 20 min, respectively (24). The plasma
proinsulin clearance is slower than that of
insulin (13,25). Although the effect of proin-
sulin is markedly lower than that of insulin
on adipocytes, its effect on hepatocytes can
reach 50% of the insulin effect (26,27). We
may assume that proinsulin may participate
to some extent in the action of insulin on
hepatocytes in terms of regulating hepatocytic
SHBG release. Further in vitro investiga-
tions are required to clarify the role of proin-
sulin as a direct regulator of hepatic SHBG
release. In the present study we confirmed
the negative correlation between greater pan-
creatic ß-cell demand and low SHBG levels.
When the stepwise regression test was ap-
plied, proinsulin was found to be the best
predictor of SHBG. We must point out that
we did not perform the insulin-glucose clamp
test which is considered to be the gold stan-
dard for assaying insulin sensitivity. Thus,
we could not confirm a correlation between
SHBG levels and insulin sensitivity. How-
ever, the negative correlation found between
SHBG levels and baseline insulinemia may
suggest the existence of this correlation since
in nondiabetic subjects insulin resistance and
fasting insulin are moderately well corre-
lated (10,28).
Obesity has been pointed out as one of
the causes of reduced SHBG levels; never-
theless, hyperinsulinemia and insulin resis-
tance secondary to obesity seem to be deter-
minant factors in this association. A fact that
could indicate the absence of the role of
obesity itself in reducing SHBG levels is the
Table 3 - Comparisons between nonobese and obese
groups.
*P<0.05 compared to nonobese (Mann-Whitney rank sum
test or Student t- test). For abbreviations, see Table 1.
Nonobese Obese
(N = 10) (N = 8)
BMI (kg/m2) 24.2 ± 0.9 34.5 ± 5.2*
Waist (cm) 85.8 ± 4.5 113.4 ± 10.6*
WHR 0.88 ± 0.03 0.96 ± 0.03*
DPX (%fat) 18.0 ± 5.0 32.5 ± 5.3*
Weight (kg) 76.4 ± 6.0 110.7 ± 19.9*
Age (year) 30.2 ± 2.5 31.1 ± 2.6
SHBG (nmol/l) 44.6 ± 13.0 31.4 ± 10.3*
Fasting insulin (µU/ml) 11.8 ± 3.4 21.0 ± 10.8
120-min insulin (µU/ml) 25.5 ± 12.7 107.5 ± 75.0*
Fasting proinsulin (pmol/l) 11.6 ± 3.0 24.9 ± 19.0*
120-min proinsulin (pmol/l) 27.4 ± 14.2 58.5 ± 18.1*
Fasting C-peptide (ng/ml) 1.7 ± 0.6 2.7 ± 1.2*
120-min C-peptide (ng/ml) 4.6 ± 2.9 7.5 ± 3.7
Proinsulin/insulin 0.16 ± 0.09 0.26 ± 0.29
Fasting glucose (mg/dl) 94 ± 9 92 ± 6
120-min glucose (mg/dl) 94 ± 21 109 ± 21
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significant negative correlation between in-
sulin concentration and SHBG in women of
normal weight with polycystic ovary syn-
drome and insulin resistance (17). In our
study a significant negative correlation be-
tween SHBG levels, WHR and %fat (DPX)
measurements was found (Table 2). WHR
measurement has been indicated as an indi-
rect insulin resistance index, reflecting a
type of abdominal obesity (29-31). No corre-
lation was observed between BMI and SHBG
levels. Thus, we suggest that the association
between obesity and low SHBG levels is at
least in part dependent on hyperinsulinemia
and insulin resistance typical of android obe-
sity. The correlation between SHBG and
insulin after adjustment for BMI has been
reported (8,31).
In conclusion, the present data show that
SHBG values and pancreatic ß-cell secretion
are negatively correlated in men. Using a
specific assay for the determination of insu-
lin we confirmed literature reports of a strong
negative correlation between insulinemia and
SHBG levels. The presently described strong
negative correlation between SHBG and pro-
insulin suggests that SHBG levels can be
used as indirect markers of increased pan-
creatic ß-cell demand. We assume that pro-
insulin may have some degree of hepatocyte
activity reducing SHBG synthesis, mainly in
hyperproinsulinemic states. Further in vitro
studies are required to elucidate this point.
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